Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 264-267

  Vergnenegre A ^a   Monnet, I ^b   Chouaid C ^c   Hureaux, J ^d   Mazieres J ^e   Quere G ^f   Lombard, J N ^g   Cumin, I ^h   Abdiche, S ⁱ   Ejnaini, C Nocent ^j   Bonnabau, H ^a   Decroisette, Ch ^k  

^a Hopital du Cluzeau   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g Cabinet de Pneumologie   (France)

^h Service d'Oncologie Radiothérapie   (France)

ⁱ hôpital Robert Boulin   (France)

^j Service de Pneumologie   (France)

^k Service de Pneumologie   (France)

more..

Author keywords

Erlotinib; Observational study; Stage IV NSCLC

Indexed keywords

ERLOTINIB;

ADULT; AGE; AGED; ARTICLE; CANCER CONTROL; DERMATITIS; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; GENDER; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SMOKING; SURVIVAL TIME; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING; SURVIVAL ANALYSIS; WITHHOLDING TREATMENT;

EID: 80053640416     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.007     Document Type: Article

References (10)

1. Institut National du Cancer. http://www.e-cancer.fr/.
2. Vray M., Hamelin B., Jaillon P. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 2005, 60:339-344. 345-339.
3. Reck M., van Zandwijk N., Gridelli C., Baliko Z., Rischin D., Allan S., et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010, 5:1616-1622.
4. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
5. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
6. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
7. Dempke W.C., Suto T., Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67::257-274.
8. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
9. Melosky B., Agulnik J., Assi H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 2008, 15:279-285.
10. Popat S., Barbachano Y., Ashley S., Norton A., O'Brien M. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Lung Cancer 2008, 59:227-231.